Fig. 9.
Hypothetical model demonstrating proposed relationship between bexarotene treatment and effects on SMC phenotype. Bexarotene activates multiple nuclear receptors, including PPARγ. The combinatorial activation of multiple receptors increases expression of multiple DUSPs, which are negative regulators of p38, thereby inhibiting the prohypertrophic and proinflammatory effects of AII.